Cargando…

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

BACKGROUND: Limited adjuvant treatment options exist for patients with high-risk surgically resected melanoma. This first-in-human study investigated the safety, tolerability and immunologic correlates of Melanoma GVAX, a lethally irradiated granulocyte–macrophage colony stimulating factor (GM-CSF)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipson, Evan J, Sharfman, William H, Chen, Shuming, McMiller, Tracee L, Pritchard, Theresa S, Salas, January T, Sartorius-Mergenthaler, Susan, Freed, Irwin, Ravi, Sowmya, Wang, Hao, Luber, Brandon, Sproul, Janice Davis, Taube, Janis M, Pardoll, Drew M, Topalian, Suzanne L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491237/ https://www.ncbi.nlm.nih.gov/pubmed/26143264 http://dx.doi.org/10.1186/s12967-015-0572-3

Ejemplares similares

Mechanisms regulating PD-L1 expression on tumor and immune cells
por: Chen, Shuming, et al.
Publicado: (2019)

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
por: Lipson, Evan J, et al.
Publicado: (2014)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

An update on GM-CSF and its potential role in melanoma management
por: O Dillman, Robert
Publicado: (2020)

Measurement of PD-L1 in melanoma: a quantitative antibody comparison
por: Sunshine, Joel C, et al.
Publicado: (2015)

Inter-Tumor Heterogeneity—Melanomas Respond Differently to GM-CSF-Mediated Activation
por: Moshe, Adi, et al.
Publicado: (2020)

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
por: Rowe, Steven P., et al.
Publicado: (2018)

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
por: Anagnostou, Valsamo, et al.
Publicado: (2020)

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
por: Eroglu, Zeynep, et al.
Publicado: (2011)

Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells
por: Xia, Yuanxuan, et al.
Publicado: (2018)

Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
por: Podaza, Enrique, et al.
Publicado: (2020)

Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts
por: Liu, Sisi, et al.
Publicado: (2020)

In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells
por: Delic, Maike, et al.
Publicado: (2022)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
por: de Gast, G C, et al.
Publicado: (2003)

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
por: Perales, Miguel-Angel, et al.
Publicado: (2008)

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma
por: Koster, Bas D., et al.
Publicado: (2019)

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
por: Santegoets, Saskia JAM, et al.
Publicado: (2014)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)

Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma
por: Miguel, Antonio, et al.
Publicado: (2017)

Dual VEGFA/BRAF targeting boosts PD‐1 blockade in melanoma through GM‐CSF‐mediated infiltration of M1 macrophages
por: Comunanza, Valentina, et al.
Publicado: (2023)

Melanoma metastatic to the hyoid bone
por: Ryan, John F., et al.
Publicado: (2020)

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node
por: van den Hout, Mari F. C. M., et al.
Publicado: (2016)

Induction of Mouse Anti‐melanoma Cytotoxic and Suppressor T Cells in vitro by an Artificial Antigen, GM3‐lactone
por: Harada, Yoshitada, et al.
Publicado: (1990)

GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy
por: Qin, L, et al.
Publicado: (2013)

Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer
por: Nair, Nitya, et al.
Publicado: (2015)

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Clinical evaluation of melanomas and common nevi by spectral imaging
por: Diebele, Ilze, et al.
Publicado: (2012)

Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma
por: Osorio, Marta, et al.
Publicado: (2012)

Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
por: Ascierto, Paolo A., et al.
Publicado: (2020)

Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4(+) T Cells
por: Pieper, Rembert, et al.
Publicado: (1999)

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Density of GM3 with Normal Primary Structure Determines Mouse Melanoma Antigenicity; a New Concept of Tumor Antigen
por: Harada, Yoshitada, et al.
Publicado: (1989)

A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder
por: Truong, Hong, et al.
Publicado: (2013)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
por: Morales, Rita E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p50dgfo85n8fadabiab23ch1gc